Old and new drugs in cardiovascular pharmacotherapy

Antiobesity pharmacotherapy: new drugs and emerging targets.

Obesity is a growing pandemic, and related health and economic costs are staggering. Pharmacotherapy, partnered with lifestyle modifications, forms the core of current strategies to reduce the burden of this disease and its sequelae. However, therapies targeting weight loss have a significant history of safety risks, including cardiovascular and psychiatric events. Here, evolving strategies for...

Drugs old and new.

Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.

WHAT IS KNOWN AND OBJECTIVE Obesity affects approximately one-third of the American population, and its prevalence continues to increase. It is a significant risk factor for cardiovascular diseases and contributes to increased healthcare costs and mortality. The objective is to review the current literature on the cardiovascular effects of weight loss pharmacotherapy agents. METHODS Literatur...

Old drugs - old people - new insights.

Dr. Dan Sitar was the recipient of the 2004 CSCP Senior Investigator Award at the First Canadian Therapeutics Congress held in June 2004. He presented a lecture highlighting some of the studies he participated in that have contributed to an increased understanding of the role of aging on drug disposition and effect.

Poisonings by Cardiovascular Drugs in Yekaterinburg, Russia

Background: The pattern of poisoning in Russia may be different from other countries. The study objective was to describe the pattern of poisoning with cardiovascular drugs in a major industrial city in Russia, Yekaterinburg. Methods: This study was part of a larger prospective multi-center study including all acute poisonings in patients older than 15 years of age in the city of Yekaterinburg...